Core Insights - Lifeward Ltd. has successfully closed a strategic partnership agreement with Oramed Pharmaceuticals, enhancing its position as a diversified biomedical innovation company with a clear path to profitability [1][2] Company Overview - Lifeward is a global leader in innovative medical technology aimed at transforming the lives of individuals with physical limitations or disabilities [1][3] - The company designs, develops, and commercializes solutions that provide functional and health benefits in both clinical and home settings [3] - Lifeward's product portfolio includes notable innovations such as the ReWalk Exoskeleton, AlterG Anti-Gravity system, MyoCycle FES System, and ReStore Exo-Suit [3] Strategic Partnership Details - The partnership with Oramed Pharmaceuticals includes the acquisition of Oramed's clinical-stage Protein Oral Delivery (POD™) technology, which opens up significant opportunities in the biotech market [2] - Lifeward has access to up to $47 million in capital from Oramed and other investors, having accessed $10 million of this capital on March 25, 2026 [2] Operational Changes - Following the partnership, Lifeward has made changes to its board of directors, indicating a strategic shift in governance to align with its new objectives [2]

Core Insights - Lifeward is transforming into a diversified biomedical innovation company with a focus on long-term growth and sustainability, highlighted by a strategic transaction with Oramed that introduces a new oral protein delivery technology platform [2][3] - The company is executing its strategy through the acquisition of powered upper-body exoskeleton technology, which complements its existing ReWalk platform and enhances operational scale [2][4] - Lifeward has improved operational efficiency, reflected in lower operating expenses and cash usage, supporting its goal of achieving positive cash flow [2][10] Strategic Developments - Lifeward has secured shareholder approval for a transformative agreement with Oramed, which includes acquiring Oramed's POD™ technology platform and potential funding of up to $47 million [3] - The lead drug candidate from the POD™ technology, ORMD-0801, aims to revolutionize type 2 diabetes treatment by providing oral insulin delivery [3] - The acquisition of upper-body exoskeleton technology is expected to be commercially launched within 18 to 24 months, enhancing Lifeward's product offerings [4] Financial Performance - In Q4 2025, Lifeward reported revenue of $5.1 million, a decrease of approximately 33% from Q4 2024, with ReWalk Personal exoskeleton sales increasing by 20% to $1.8 million [11] - For the full year 2025, total revenue was $22.0 million, down 14% from 2024, with notable declines in sales of the MyoCycle FES bike and AlterG products [17] - The company achieved a gross margin of 21.4% in Q4 2025, down from 24.4% in Q4 2024, primarily due to lower sales volumes and increased tariffs [12] Operational Efficiency - Lifeward's total operating expenses in Q4 2025 decreased by 64% to $6.2 million, largely due to a prior impairment charge and reductions in R&D and marketing expenses [13] - The company’s operating loss narrowed by 66% to $5.1 million in Q4 2025, compared to $15.2 million in Q4 2024 [14] - For the full year 2025, total operating expenses declined by 25% to $28.1 million, reflecting improved efficiency in reimbursement activities and lower R&D spending [19] Market Expansion - Lifeward has made significant progress in expanding reimbursement coverage for the ReWalk Personal Exoskeleton, with major payers like Aetna, Humana, and UnitedHealthcare now providing access to approximately 16 million covered lives in the U.S. [5][6] - The company is also expanding its international distribution of the ReWalk® Personal Exoskeleton into Mexico, Thailand, and the UAE through a partnership with Verita Neuro [8] - Lifeward is transforming its U.S. sales and distribution infrastructure to a hybrid model, focusing on direct-to-patient engagement and capital equipment sales [9]

Core Viewpoint - Lifeward Ltd. has regained compliance with Nasdaq's minimum bid price requirement, allowing its shares to continue trading on the Nasdaq Capital Market [1][2]. Company Overview - Lifeward is a global leader in innovative medical technology aimed at transforming the lives of individuals with physical limitations or disabilities [1]. - The company designs, develops, and commercializes solutions for physical rehabilitation and recovery, with a mission to drive innovation for individuals with disabilities [3]. - Lifeward's product portfolio includes the ReWalk Exoskeleton, AlterG Anti-Gravity System, MyoCycle FES System, and ReStore Exo-Suit [3]. Compliance Details - To regain compliance, Lifeward's common stock needed to maintain a minimum closing bid price of $1.00 for at least 10 consecutive business days, which was achieved on March 9, 2026 [2]. - The Nasdaq Listing Qualifications Staff has closed the prior bid price deficiency matter, confirming Lifeward's compliance [2]. Company History - Founded in 2001, Lifeward operates in the United States, Israel, and Germany [4]. - The company is committed to delivering groundbreaking solutions that empower individuals to engage in activities they love [3].

Core Viewpoint - Lifeward Ltd. will release its fourth quarter and full year 2025 financial results on March 18, 2026, before market opening [1] Group 1: Financial Results Announcement - The financial results will be discussed in a conference call and live webcast hosted by the President and CEO, Mark Grant, and CFO, Almog Adar, at 8:30 a.m. EST on the same day [2] - Analysts and investors can access the call through various toll-free numbers and an access code referencing "Lifeward Earnings Call" [2] Group 2: Company Overview - Lifeward is a global leader in innovative medical technology aimed at transforming the lives of individuals with physical limitations or disabilities [3] - The company designs, develops, and commercializes solutions that provide functional and health benefits in both clinical and home settings [3] - Lifeward's product portfolio includes the ReWalk Exoskeleton, AlterG Anti-Gravity system, MyoCycle FES System, and ReStore Exo-Suit [3] Group 3: Company Background - Founded in 2001, Lifeward operates in the United States, Israel, and Germany [4] - The company's mission is to drive innovation to empower individuals with physical limitations or disabilities [3][4]

Core Insights - Lifeward Ltd. has appointed Bob Marshall as the new Chairman of the Board, effective January 1, 2026, succeeding Joseph Turk who is transitioning to a new role at Fresenius Medical Care [1][2] Company Overview - Lifeward is a global leader in innovative medical technology aimed at transforming the lives of individuals with physical limitations or disabilities [3] - The company designs, develops, and commercializes solutions for physical rehabilitation and recovery, with a mission to drive innovation for individuals with disabilities [3] - Lifeward's product portfolio includes the ReWalk Exoskeleton, AlterG Anti-Gravity System, ReStore Exo-Suit, and MyoCycle FES System [3] - Founded in 2001, Lifeward operates in the United States, Israel, and Germany [3] Leadership Changes - Bob Marshall has been a member of Lifeward's Board and Chair of the Audit Committee since 2024, bringing financial leadership and healthcare expertise to the role [2] - Prior to joining Lifeward, Bob Marshall served as Chief Financial Officer and Treasurer of Lantheus Holdings since 2018 and held various positions at Zimmer Biomet Holdings [2]

Core Insights - Lifeward Ltd. has entered into a distribution agreement with Verita Neuro to expand access to the ReWalk Personal Exoskeleton for spinal cord injury patients, targeting a total addressable market of approximately $1.75 billion [1][3] Group 1: Distribution Agreement - The agreement allows Verita Neuro to be the exclusive distributor of ReWalk in Mexico, Thailand, and the UAE, leveraging its established international presence [1][3] - Verita Neuro has a database of over 25,000 spinal cord injury patients and a network of rehabilitation centers, enhancing the reach of ReWalk [2] Group 2: Commercial Strategy - Lifeward's hybrid commercial model combines direct sales in the U.S. with third-party distribution in select international markets, aiming for increased sales volumes while managing operating expenses [3] - The partnership with Verita Neuro is intended to integrate ReWalk into their multi-modal treatment methodologies, which include surgical neural stimulation and stem cell therapy [3][4] Group 3: Rehabilitation Approach - Verita Neuro will implement a new delivery model that includes intensive in-patient training and rehabilitation for ReWalk, differing from the traditional outpatient training [4] - This approach is expected to enhance clinical adoption of ReWalk in various rehabilitation settings globally [4]

Core Insights - Lifeward Ltd. has received prior authorization from Humana Medicare Advantage Plan for its ReWalk 7 Personal Exoskeleton, marking a significant step in expanding access to innovative medical technology for individuals with spinal cord injuries [1][2][3] - Humana and UnitedHealthcare, the two largest Medicare Advantage providers in the U.S., now account for 47% of all Medicare Advantage enrollees eligible for reimbursement for the ReWalk 7 [1][3] Company Developments - The approval from Humana is expected to enhance Lifeward's revenue and cash flow dynamics, providing a clearer foundation for scalable growth in the U.S. market [1][3] - Lifeward has been actively submitting claims for reimbursement under both traditional Medicare and Medicare Advantage Plans since the Centers for Medicare & Medicaid Services (CMS) implemented a formal reimbursement pathway for personal exoskeletons in 2024 [3] Industry Context - The approval of coverage for the ReWalk 7 under Humana's Medicare Advantage Plan reflects a broader trend of increasing acceptance of innovative medical technologies within the healthcare system [2][3] - Nearly half of all Medicare Advantage enrollees are now eligible for prior authorization and reimbursement for the ReWalk 7, indicating a growing recognition of the clinical and functional value of personal exoskeleton technology [3]

Core Viewpoint - Lifeward Ltd. has received its first prior authorization from a UnitedHealthcare Medicare Advantage Plan for the ReWalk 7 Personal Exoskeleton, marking a significant step in expanding reimbursement pathways for advanced assistive technology for individuals with spinal cord injuries [1][2][3]. Company Summary - Lifeward is a global leader in innovative medical technology aimed at transforming the lives of individuals with physical limitations or disabilities, with a mission to drive innovation and deliver groundbreaking solutions [5]. - The company’s product portfolio includes the ReWalk Exoskeleton, AlterG Anti-Gravity System, ReStore Exo-Suit, and MyoCycle FES System, and it operates in the United States, Israel, and Germany [5]. Industry Summary - UnitedHealthcare's approval for the ReWalk 7 demonstrates a commitment to providing access to advanced assistive technology, enhancing mobility and quality of life for individuals with spinal cord injuries [2][3]. - The approval reflects a proactive approach in expanding reimbursement pathways, ensuring reliable access to personal exoskeletons as part of a comprehensive care strategy [3]. - The Centers for Medicare & Medicaid Services (CMS) implemented a reimbursement pathway for personal exoskeletons in 2024, leading to an acceleration in prior authorizations as payer adoption expands [4].

Core Viewpoint - Lifeward Ltd. will release its third quarter 2025 financial results on November 14, 2025, before market opening [1] Group 1: Financial Results Announcement - The financial results will be discussed in a conference call and live webcast hosted by the President and CEO, Mark Grant, and CFO, Almog Adar, at 8:30 a.m. EST on the same day [2] - Analysts and investors can access the call through various toll-free numbers and an access code referencing "Lifeward Earnings Call" [2] Group 2: Company Overview - Lifeward is a global leader in innovative medical technology aimed at transforming the lives of individuals with physical limitations or disabilities [1][3] - The company designs, develops, and commercializes solutions that provide functional and health benefits in both clinical and home settings [3] - Lifeward's product portfolio includes the ReWalk Exoskeleton, AlterG Anti-Gravity system, MyoCycle FES System, and ReStore Exo-Suit [3] Group 3: Company Background - Founded in 2001, Lifeward operates in the United States, Israel, and Germany [4] - The company's mission is to drive innovation to empower individuals with physical limitations [3][4]

Core Insights - Lifeward Ltd. has appointed Almog Adar as the new Chief Financial Officer, succeeding his previous role as Vice President of Finance and Chief Accounting Officer [1][3] - The appointment is seen as a strategic move to support the company's growth and strengthen its financial foundation [2][3] Company Overview - Lifeward is a global leader in innovative medical technology aimed at transforming the lives of individuals with physical limitations or disabilities [1][6] - The company designs, develops, and commercializes solutions that provide functional and health benefits in both clinical and home settings [6] - Lifeward's product portfolio includes notable innovations such as the ReWalk Exoskeleton, AlterG Anti-Gravity system, MyoCycle FES System, and ReStore Exo-Suit [6] Leadership Background - Almog Adar joined Lifeward in 2020 and has held various senior roles, contributing to the company's financial strategy and operations [3][4] - Prior to Lifeward, Mr. Adar gained extensive experience in financial management at Infinya Recycling Ltd. and Delta Galil Industries, as well as auditing at Ernst & Young [4][5] - He holds a Bachelor of Arts degree in Accounting and Economics and is a Certified Public Accountant licensed in Israel [5] Strategic Vision - Mr. Adar expressed commitment to enhancing Lifeward's execution and accelerating growth through a disciplined strategy [3] - The company aims to leverage its strengths to create lasting value for patients, customers, and shareholders [3] Company History - Lifeward was founded in 2001 and operates in the United States, Israel, and Germany [7] - The company's mission focuses on relentless innovation to improve the lives of individuals with physical limitations or disabilities [6]